Evolocumab Brand Name– REPATHA
What is Evolocumab
Evolocumab is a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor indicated as an adjunct treatment to diet, alone or in combination with other lipid-lowering therapies (e.g., statins, ezetimibe), in adults with primary hyperlipidemia (including heterozygous familial hypercholesterolemia) or for adjunct treatment to diet and other low density lipoprotein cholesterol (LDL-C) lowering therapies in adolescents and adults with homozygous familial hypercholesterolemia who require additional lowering of LDL-C.
Evolocumab also is indicated to reduce the risk of myocardial infarction, stroke, and coronary revascularization in adults with established cardiovascular disease. During various clinical trials, evolocumab produced negative mean differences from placebo from baseline in LDL-C ranging from 54% to 71%.
Evolocumab was FDA-approved in August 2015.
Indications
- heterozygous familial hypercholesterolemia
- homozygous familial hypercholesterolemia
- hypercholesterolemia
- myocardial infarction prophylaxis
- stroke prophylaxis
Note: Evolocumab is recommended as second-line therapy in addition to maximally tolerated statin therapy in patients with clinical ASCVD and comorbidities that still require 25% or greater LDL reduction. Factors to consider include cost, benefit of ASCVD risk reduction, dosing frequency requirements, and administration by subcutaneous injection.
Side Effects
- angioedema
- antibody formation
- arthralgia
- back pain
- cough
- diarrhea
- dizziness
- erythema
- headache
- hyperglycemia
- hypertension
- infection
- influenza
- injection site reaction
- musculoskeletal pain
- myalgia
- nausea
- pharyngitis
- rash
- sinusitis
- urticaria
Monitoring Parameters
- serum lipid profile
Contraindications
- breast-feeding
- latex hypersensitivity
- pregnancy
Interactions
There are no drug interactions associated with Evolocumab products.
